Diagnostic Imaging's Weekly Scan: Nov. 27, 2020
Low-dose CT for lung cancer screening offers significant benefits for detection and follow-up, but utilization, to date, has been low. Debra S. Dyer, M.D., chair of the American College of Radiology's Lung Cancer Screening 2.0 Committee discusses what the screening provides and the challenges to more widespread implementation.
Welcome to Diagnostic Imaging. I’m senior editor, Whitney Palmer
It’s Lung Cancer Awareness month, and one of the biggest advancements in the detection of the disease in recent years has been low-dose CT for screening. Not only does this technique offer a way to pinpoint whether a patient has lung cancer without exposing him or her to high levels of radiation, but it also provides a safe way to conduct multiple follow-up scans, as needed.
However, to date, utilization of this low-dose method has fallen well below expectations and hopes. With only 4.5 percent to 5 percent of eligible patients actually getting scanned, there’s a lot of room for improvement. This week, Diagnostic Imaging spoke with Dr. Debra Dyer, chair of the American College of Radiology’s Lung Cancer Screening 2.0 Committee about the benefits of low-dose CT, the challenges that exist to wider adoption and implementation, and what providers and facilities can do to increase screening rates.
Here’s what she had to say.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
